Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.55 |
| ▸ | BRAF | P15056 | 1/20 | 0.50 |
| ▸ | NEK2 | P51955 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 3/20 | 0.46 |
| ▸ | STAT3 | P40763 | 3/20 | 0.45 |
| ▸ | SYK | P43405 | 2/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.43 |
| ▸ | BTK | Q06187 | 4/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | PAK4 | O96013 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31506448 | 1.00 | GDA (0.55) | GDABRAFNEK2SRCSTAT3 | |
| SCHEMBL887125 | 0.84 | GDA (0.55) | GDABRAFNEK2SRCSTAT3 | |
| SCHEMBL16146679 | 0.84 | GDA (0.55) | GDABRAFNEK2SRCXDH | |
| SCHEMBL16146528 | 0.84 | GDA (0.55) | GDABRAFNEK2SRCXDH | |
| SCHEMBL5694222 | 0.84 | GDA (0.55) | GDABRAFNEK2SRCPTK2 | |
| SCHEMBL16145715 | 0.83 | GDA (0.54) | GDABRAFNEK2SRCXDH | |
| SCHEMBL16146643 | 0.83 | MGMT (0.55) | GDABRAF | |
| SCHEMBL5197101 | 0.83 | GDA (0.54) | GDABRAFNEK2SRCSTAT3 | |
| SCHEMBL16146215 | 0.83 | GDA (0.54) | GDABRAFNEK2SRCXDH | |
| SCHEMBL14938904 | 0.83 | GDA (0.54) | GDABRAFNEK2SRCXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430032-B1 | METHOD FOR THE MANUFACTURE OF 2-FLUORO-ARA-ADENINE | ALCAFLEU MAN GMBH & CO KG (DE) | 2016-02-17 | — | — | EP | disclosed |
| US-20120220762-A1 | METHOD FOR THE MANUFACTURE OF 2-FLUORO-ARA-ADENINE | ALCAFLEU MANAGEMENT GMBH & CO. KG (DE) | 2012-08-30 | — | — | US | disclosed |
| EP-2430032-A1 | METHOD FOR THE MANUFACTURE OF 2-FLUORO-ARA-ADENINE | Alcafleu Management GmbH & Co. KG (DE) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010130778-A1 | METHOD FOR THE MANUFACTURE OF 2-FLUORO-ARA-ADENINE | ALCAFLEU MANAGEMENT GMBH & CO. KG (DE) | 2010-11-18 | — | — | WO | disclosed |
| CN-1221609-A | Pharmaceutical use of adenosine phosphates and pharmaceutical preparation thereof | KARL Y HOSTETLER (US) | 1999-07-07 | — | — | CN | disclosed |
| CN-1220605-A | Nucleotide analogues for topical treatment of skin cell proliferative disorders | KARL Y HOSTETLER (US) | 1999-06-23 | — | — | CN | disclosed |
| EP-0831855-A1 | NUCLEOTIDE ANALOGUES FOR TOPICAL TREATMENT OF PROLIFERATIVE DISEASE OF THE SKIN | HOSTETLER, Karl Y. (US) | 1998-04-01 | — | — | EP | disclosed |
| US-5654286-A | Nucleotides for topical treatment of psoriasis, and methods for using same | HOSTETLER KARL Y (US) | 1997-08-05 | — | — | US | disclosed |
| WO-1996040166-A1 | NUCLEOTIDE ANALOGUES FOR TOPICAL TREATMENT OF PROLIFERATIVE DISEASE OF THE SKIN | HOSTETLER KARL Y (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0456817-B1 | PROCESS FOR THE PREPARATION OF 2-AMINO-9-(2,3,5-TRI-0-BENZYL-BETA-D-ARABINOFURANOSYL)ADENINE AND NOVEL INTERMEDIATES | ASH STEVENS INC (US) | 1996-01-31 | — | — | EP | disclosed |
| EP-0456817-A4 | PROCESS FOR THE PREPARATION OF 2-AMINO-9-(2,3,5-TRI-0-BENZYL-BETA-D-ARABINOFURANOSYL)ADENINE AND NOVEL INTERMEDIATES | — | 1992-04-22 | — | — | EP | disclosed |
| EP-0456817-A1 | PROCESS FOR THE PREPARATION OF 2-AMINO-9-(2,3,5-TRI-0-BENZYL-BETA-D-ARABINOFURANOSYL)ADENINE AND NOVEL INTERMEDIATES. | ASH STEVENS INC (US) | 1991-11-21 | — | — | EP | disclosed |
| WO-1991008215-A1 | PROCESS FOR THE PREPARATION OF 2-AMINO-9-(2,3,5-TRI-0-BENZYL-BETA-D-ARABINOFURANOSYL)ADENINE AND NOVEL INTERMEDIATES | ASH STEVENS, INC. (US) | 1991-06-13 | — | — | WO | disclosed |
| US-4883917-A | Quaternary ammonium compounds | ETHYL CORPORATION (US) | 1989-11-28 | — | — | US | disclosed |
| US-4849423-A | Purine derivatives, medicaments containing them and methods of treating cardiac insufficiencies and irregularities with them. | SANDOZ LTD. (CH) | 1989-07-18 | — | — | US | disclosed |
| EP-0311108-A2 | Anti-HIV active 3'-azido-2,6-diaminopurine-2',3'-dideoxyriboside | Stichting REGA V.Z.W. (BE) | 1989-04-12 | — | — | EP | disclosed |
| US-4210745-A | Procedure for the preparation of 9-β-D-arabinofuranosyl-2-fluoroadenine | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH, EDUCATION AND WELFARE (US) | 1980-07-01 | — | — | US | disclosed |
| US-4210745-A | Procedure for the preparation of 9-β-D-arabinofuranosyl-2-fluoroadenine | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH, EDUCATION AND WELFARE (US) | 1980-07-01 | — | — | US | disclosed |
| US-4188378-A | Anticancer and antiviral activity of 9-β-D-arabinofuranosyl-2-fluoroadenine | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH, EDUCATION AND WELFARE (US) | 1980-02-12 | — | — | US | disclosed |
| US-3992531-A | 2-Substituted adenosine-5'-carboxylates in the treatment of anginal pain | ABBOTT LABORATORIES (US) | 1976-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220762-A1 | METHOD FOR THE MANUFACTURE OF 2-FLUORO-ARA-ADENINE | CD38, FLAD1, GART | GDA 193/4885BRAF 286/4885NEK2 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.